Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation-Reference-Cited by-同舟云学术

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

Published:2020-05 Issue:3 Volume:21 Page:273-280.e4
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Tanaka Ichidai^ORCID,Morise Masahiro,Miyazawa Ayako,Kodama Yuta,Tamiya Yutaro,Gen Soei,Matsui Akira,Hase Tetsunari^ORCID,Hashimoto Naozumi,Sato Mitsuo,Hasegawa Yoshinori

Funder

Boehringer Ingelheim

Pfizer Inc

Astellas Pharma Inc

Ono Pharmaceutical Co

Shionogi & Co

AstraZeneca

Sanofi KK

Teijin Limited

MSD KK

Meiji Seika Pharma Co

Daiichi Sankyo Company Ltd

GlaxoSmithKline KK

Otsuka Pharmaceutical Co

KYORIN Pharmaceutical Co Ltd

Sumitomo Dainippon Pharma Co

Novartis Pharma KK

Kyowa Hakko Kirin Co

Eli Lilly Japan KK

Chugai Pharmaceutical Co

Nagoya University

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Cancer,2019

2. Non–small-cell lung cancers: a heterogeneous set of diseases;Chen;Nat Rev Cancer,2014

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

4. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers;Shigematsu;J Natl Cancer Inst,2005

5. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors;Journal of Cancer Research and Clinical Oncology;2024-04-30

2. Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter study;2024-02-15

3. Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion;Advances in Therapy;2023-10-06

4. Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer;2023-09-15

5. Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies;Frontiers in Oncology;2023-08-22